

Borja G. Cosio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5453195/publications.pdf>

Version: 2024-02-01

164
papers

8,494
citations

81434

41
h-index

56606

87
g-index

182
all docs

182
docs citations

182
times ranked

7776
citing authors

#	ARTICLE	IF	CITATIONS
1	Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 150-161.	2.7	35
2	Impact of Blood Eosinophil Variability in Asthma: A Real-Life Population Study. <i>Annals of the American Thoracic Society</i> , 2022, 19, 407-414.	1.5	11
3	Asthmaâ€”COPD Overlap. , 2022, , 702-711.		0
4	Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 63-78.	1.5	41
5	Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 79-88.	1.5	13
6	Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1202-1216.e23.	2.0	22
7	[Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. <i>Archivos De Bronconeumologia</i> , 2022, 58, T69-T81.	0.4	27
8	Is it Time to Readjust the Doses of Inhaled Corticosteroids in COPD?. <i>Archivos De Bronconeumologia</i> , 2022, 58, 593-594.	0.4	7
9	[Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care. <i>Archivos De Bronconeumologia</i> , 2022, 58, T334-T344.	0.4	4
10	[Translated article] Spanish COPD Guidelines (GesEPOC) 2021 Update. Diagnosis and Treatment of COPD Exacerbation Syndrome. <i>Archivos De Bronconeumologia</i> , 2022, 58, T159-T170.	0.4	16
11	[Translated article] Spanish COPD Guidelines (GesEPOC 2021): Non-pharmacological Treatment Update. <i>Archivos De Bronconeumologia</i> , 2022, 58, T345-T351.	0.4	8
12	Determinants of blood eosinophil levels in the general population and patients with COPD: a population-based, epidemiological study. <i>Respiratory Research</i> , 2022, 23, 49.	1.4	10
13	The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthmaâ€”COPD Overlap Syndrome. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 363-369.	1.5	8
14	Hsa-Mir-320c, Hsa-Mir-200c-3p, and Hsa-Mir-449c-5p as Potential Specific miRNA Biomarkers of COPD: A Pilot Study. <i>Pathophysiology</i> , 2022, 29, 143-156.	1.0	5
15	Prevalence and Determinants of COPD in Spain: EPISCAN II. <i>Archivos De Bronconeumologia</i> , 2021, 57, 61-69.	0.4	103
16	Clinical Control Criteria to Determine Disease Control in Patients with Severe COPD: The CLAVE Study. <i>International Journal of COPD</i> , 2021, Volume 16, 137-146.	0.9	2
17	COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort. <i>Respiratory Research</i> , 2021, 22, 36.	1.4	2
18	Sobre la enfermedad pulmonar obstructiva crÃ³nica y el big data. <i>Archivos De Bronconeumologia</i> , 2021, 57, 144.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Work absence in patients with asthma and/or COPD: a population-based study. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 9.	1.1	8
20	Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2725-2731.	2.0	24
21	Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 260-274.	5.2	102
22	Telerehabilitation Programme as a Maintenance Strategy for COPD Patients: A 12-Month Randomized Clinical Trial. <i>Archivos De Bronconeumologia</i> , 2021, 57, 195-204.	0.4	26
23	Telerehabilitation Programme as a Maintenance Strategy for COPD Patients: A 12-Month Randomized Clinical Trial. <i>Archivos De Bronconeumologia</i> , 2021, 57, 195-204.	0.4	6
24	Adhesi3n terap3utica de los pacientes con EPOC seg3n los niveles de implicaci3n en educaci3n sanitaria de sus centros. <i>Archivos De Bronconeumologia</i> , 2021, 57, 307-309.	0.4	1
25	Therapeutic adherence of COPD patients according to levels of involvement in health education in their sites. <i>Archivos De Bronconeumologia</i> , 2021, 57, 307-309.	0.4	0
26	Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. <i>Archivos De Bronconeumologia</i> , 2021, 58, T69-T69.	0.4	13
27	Characterization of COPD Admissions During the First COVID-19 Outbreak. <i>International Journal of COPD</i> , 2021, Volume 16, 1549-1554.	0.9	6
28	Predicting mortality for patients with heart failure beyond oxygen consumption: a prognostic risk score. <i>Journal of Applied Physiology</i> , 2021, 131, 1251-1259.	1.2	0
29	Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD. <i>Chest</i> , 2021, 160, 481-490.	0.4	16
30	Eosinophilic and Noneosinophilic Asthma. <i>Chest</i> , 2021, 160, 814-830.	0.4	109
31	Implementation of an Integrated Care Model for Frequent-Exacerbator COPD Patients: A Controlled Prospective Study. <i>Archivos De Bronconeumologia</i> , 2021, 57, 577-583.	0.4	3
32	Implementation of an Integrated Care Model for Frequent-Exacerbator COPD Patients: A Controlled Prospective Study. <i>Archivos De Bronconeumologia</i> , 2021, 57, 577-583.	0.4	11
33	Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. <i>Chest</i> , 2021, 160, 872-878.	0.4	22
34	Prevalence and Determinants of COPD in Spain: EPISCAN II. <i>Archivos De Bronconeumologia</i> , 2021, 57, 61-69.	0.4	27
35	Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome. <i>Archivos De Bronconeumologia</i> , 2021, , .	0.4	3
36	Inhaled corticosteroid dose is associated with infection in severe COPD. <i>BMJ Open Respiratory Research</i> , 2021, 8, .	1.2	1

#	ARTICLE	IF	CITATIONS
37	Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD. <i>Frontiers in Medicine</i> , 2021, 8, 761767.	1.2	5
38	Inhaled corticosteroid dose is associated with <i>Pseudomonas aeruginosa</i> infection in severe COPD. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001067.	1.2	7
39	Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 940-942.	2.7	5
40	Eosinophilic COPD Patients Display a Distinctive Serum miRNA Profile From Asthma and Non-eosinophilic COPD. <i>Archivos De Bronconeumologia</i> , 2020, 56, 234-241.	0.4	17
41	International Severe Asthma Registry. <i>Chest</i> , 2020, 157, 805-814.	0.4	38
42	Determinants and Differences in Satisfaction with the Inhaler Among Patients with Asthma or COPD. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 645-653.	2.0	11
43	Phenotypic characterisation of early COPD: a prospective case-control study. <i>ERJ Open Research</i> , 2020, 6, 00047-2020.	1.1	21
44	Time for a change: anticipating the diagnosis and treatment of COPD. <i>European Respiratory Journal</i> , 2020, 56, 2002104.	3.1	33
45	A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients. <i>International Journal of COPD</i> , 2020, Volume 15, 1801-1811.	0.9	2
46	Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: A prospective study. <i>PLoS ONE</i> , 2020, 15, e0238216.	1.1	60
47	International severe asthma registry (ISAR): protocol for a global registry. <i>BMC Medical Research Methodology</i> , 2020, 20, 212.	1.4	29
48	A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future. <i>International Journal of COPD</i> , 2020, Volume 15, 2091-2100.	0.9	27
49	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. <i>ERJ Open Research</i> , 2020, 6, 00253-2020.	1.1	10
50	Eosinophilic COPD Patients Display a Distinctive Serum miRNA Profile From Asthma and Non-eosinophilic COPD. <i>Archivos De Bronconeumologia</i> , 2020, 56, 234-241.	0.4	8
51	Hospital Epidemics Tracker (HEpiTracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e21653.	1.2	13
52	Nuevo estudio sobre la prevalencia de la EPOC en España: resumen del protocolo EPISCAN II, 10 años después de EPISCAN. <i>Archivos De Bronconeumologia</i> , 2019, 55, 38-47.	0.4	30
53	EARLY COPD: determinantes de la aparición y progresión de la enfermedad pulmonar obstructiva crónica en adultos jóvenes. Protocolo de un estudio caso-control con seguimiento. <i>Archivos De Bronconeumologia</i> , 2019, 55, 312-318.	0.4	8
54	ACO: Time to move from the description of different phenotypes to the treatable traits. <i>PLoS ONE</i> , 2019, 14, e0210915.	1.1	42

#	ARTICLE	IF	CITATIONS
55	The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , 2019, 55, 93-99.	0.4	5
56	Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A Case-Control Study With Follow-Up. <i>Archivos De Bronconeumologia</i> , 2019, 55, 312-318.	0.4	4
57	Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients. <i>BMC Pulmonary Medicine</i> , 2019, 19, 112.	0.8	28
58	Circulating miRNAs as diagnostic tool for discrimination of respiratory disease: Asthma, asthma-chronic obstructive pulmonary disease (COPD) overlap and COPD. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2491-2494.	2.7	13
59	Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study. <i>Respiratory Medicine</i> , 2019, 151, 49-54.	1.3	27
60	Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2277-2283.e2.	2.0	33
61	Severe T2-high asthma in the biologics era: European experts' opinion. <i>European Respiratory Review</i> , 2019, 28, 190054.	3.0	32
62	10 Years After EPISCAN: A New Study on the Prevalence of COPD in Spain-A Summary of the EPISCAN II Protocol. <i>Archivos De Bronconeumologia</i> , 2019, 55, 38-47.	0.4	10
63	Proyecto de biomarcadores y perfiles clínicos personalizados en la enfermedad pulmonar obstructiva crónica (proyecto BIOMEPOC). <i>Archivos De Bronconeumologia</i> , 2019, 55, 93-99.	0.4	18
64	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 578-588.e2.	2.0	39
65	The Post-truth Behind the Asthma-COPD Overlap and the Orbit of Mercury: Lessons From the CHACOS Study. <i>Archivos De Bronconeumologia</i> , 2018, 54, 175-176.	0.4	1
66	Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease. <i>Archivos De Bronconeumologia</i> , 2018, 54, 198-204.	0.4	2
67	Papel de la medicina de la FE NO en el diagnóstico y control del asma. Debate del grupo multidisciplinar de expertos de la reunión Asma Meeting Point 2017. <i>Archivos De Bronconeumologia</i> , 2018, 54, 237-238.	0.4	0
68	Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease. <i>Archivos De Bronconeumologia</i> , 2018, 54, 198-204.	0.4	24
69	Valoración funcional respiratoria previa a la reducción de volumen pulmonar en pacientes con enfisema. <i>Archivos De Bronconeumologia</i> , 2018, 54, 251-252.	0.4	0
70	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. <i>BMC Medicine</i> , 2018, 16, 33.	2.3	21
71	La posverdad detrás del solapamiento entre asma y EPOC y la órbita de Mercurio. Lecciones del estudio CHACOS. <i>Archivos De Bronconeumologia</i> , 2018, 54, 175-176.	0.4	3
72	Changes and Clinical Consequences of Smoking Cessation in Patients With COPD. <i>Chest</i> , 2018, 154, 274-285.	0.4	6

#	ARTICLE	IF	CITATIONS
73	The importance of symptoms in the longitudinal variability of clusters in COPD patients: A validation study. <i>Respirology</i> , 2018, 23, 485-491.	1.3	9
74	The dose of inhaled corticosteroids in patients with COPD: when less is better. <i>International Journal of COPD</i> , 2018, Volume 13, 3539-3547.	0.9	34
75	What is early COPD and why is it important?. <i>European Respiratory Journal</i> , 2018, 52, 1801448.	3.1	90
76	Asthmaâ€“COPD overlap: identification and optimal treatment. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880566.	1.0	35
77	Mixed Th2 and non-Th2 inflammatory pattern in the asthma–COPD overlap: a network approach. <i>International Journal of COPD</i> , 2018, Volume 13, 591-601.	0.9	44
78	Temporal transitions in COPD severity stages within the GOLD 2017 classification system. <i>Respiratory Medicine</i> , 2018, 142, 81-85.	1.3	12
79	Bone marrow characterization in COPD: a multi-level network analysis. <i>Respiratory Research</i> , 2018, 19, 118.	1.4	8
80	Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. , 2018, , .		5
81	The impact of asthma and/or COPD on work absence. , 2018, , .		0
82	Chronic Obstructive Pulmonary Disease in Non-Smokers. <i>Archivos De Bronconeumologia</i> , 2017, 53, 45-46.	0.4	3
83	El test de adhesiÃ³n a los inhaladores. <i>Archivos De Bronconeumologia</i> , 2017, 53, 360-361.	0.4	20
84	Algorithm for identification of asthmaâ€“COPD overlap: consensus between the Spanish COPD and asthma guidelines. <i>European Respiratory Journal</i> , 2017, 49, 1700068.	3.1	75
85	Th-2 signature in chronic airway diseases: towards the extinction of asthmaâ€“COPD overlap syndrome?. <i>European Respiratory Journal</i> , 2017, 49, 1602397.	3.1	55
86	Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , 2017, 53, 324-335.	0.4	30
87	Consensus on the Asthmaâ€“COPD Overlap (ACO) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). <i>Archivos De Bronconeumologia</i> , 2017, 53, 443-449.	0.4	31
88	Test of Adherence to Inhalers. <i>Archivos De Bronconeumologia</i> , 2017, 53, 360-361.	0.4	6
89	Multi-level differential network analysis of COPD exacerbations. <i>European Respiratory Journal</i> , 2017, 50, 1700075.	3.1	38
90	A simple algorithm for the identification of clinical COPD phenotypes. <i>European Respiratory Journal</i> , 2017, 50, 1701034.	3.1	53

#	ARTICLE	IF	CITATIONS
91	Is There Room for Theophylline in COPD?. Archivos De Bronconeumologia, 2017, 53, 539-540.	0.4	3
92	Reply to Chiappetta et al. European Journal of Cardio-thoracic Surgery, 2017, 51, 195.2-195.	0.6	0
93	Consenso sobre el solapamiento de asma y EPOC (ACO) entre la Guía española de la EPOC (GesEPOC) y la Guía Española para el Manejo del Asma (GEMA). Archivos De Bronconeumologia, 2017, 53, 443-449.	0.4	102
94	¿Hay un lugar para la teofilina en la EPOC?. Archivos De Bronconeumologia, 2017, 53, 539-540.	0.4	5
95	Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable. Archivos De Bronconeumologia, 2017, 53, 324-335.	0.4	365
96	Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. European Respiratory Journal, 2017, 50, 1701162.	3.1	122
97	Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2017, 18, 1097.e11-1097.e24.	1.2	38
98	Enfermedad pulmonar obstructiva crónica de origen no tabáquico. Archivos De Bronconeumologia, 2017, 53, 45-46.	0.4	7
99	Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research – a consensus document from six scientific societies. International Journal of COPD, 2017, Volume 12, 2593-2610.	0.9	44
100	The EASI model: A first integrative computational approximation to the natural history of COPD. PLoS ONE, 2017, 12, e0185502.	1.1	4
101	Asthma-COPD overlap is not a homogeneous disorder: further supporting data. Respiratory Research, 2017, 18, 183.	1.4	28
102	A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respiratory Research, 2017, 18, 198.	1.4	38
103	Multiple Score Comparison: a network meta-analysis approach to comparison and external validation of prognostic scores. BMC Medical Research Methodology, 2017, 17, 172.	1.4	7
104	Blood cytokine expression in patients with chronic obstructive airway diseases (COAD). , 2017, , .		0
105	What does a highly positive bronchodilator test indicate in a patient with chronic airflow obstruction?. , 2017, , .		0
106	Usefulness of Bronchoscopic Probe-Based Confocal Laser Endomicroscopy in the Diagnosis of Pneumocystis jirovecii and Pneumonia. Respiration, 2016, 92, 40-47.	1.2	16
107	Asma, enfermedad pulmonar obstructiva crónica y otros combinados. Archivos De Bronconeumologia, 2016, 52, 499-500.	0.4	4
108	Risk of postoperative complications in chronic obstructive lung diseases patients considered fit for lung cancer surgery: beyond oxygen consumption. European Journal of Cardio-thoracic Surgery, 2016, 50, 772-779.	0.6	40

#	ARTICLE	IF	CITATIONS
109	Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD. <i>Chest</i> , 2016, 150, 123-130.	0.4	50
110	The inflammasome pathway in stable COPD and acute exacerbations. <i>ERJ Open Research</i> , 2016, 2, 00002-2016.	1.1	47
111	Asthma, Chronic Obstructive Pulmonary Disease and Other Combinations. <i>Archivos De Bronconeumologia</i> , 2016, 52, 499-500.	0.4	3
112	Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. <i>Chest</i> , 2016, 149, 45-52.	0.4	227
113	Differences in Adherence and Non-Adherence Behaviour Patterns to Inhaler Devices Between COPD and Asthma Patients. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 547-554.	0.7	40
114	Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. <i>Annals of the American Thoracic Society</i> , 2016, 13, 636-642.	1.5	19
115	Comorbidity, Pattern, and Impact of Asthma-COPD Overlap Syndrome in Real Life. <i>Chest</i> , 2016, 149, 1011-1020.	0.4	113
116	Validation of the "Test of the Adherence to Inhalers"™ (TAI) for Asthma and COPD Patients. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2016, 29, 142-152.	0.7	146
117	Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort. <i>PLoS ONE</i> , 2016, 11, e0160770.	1.1	57
118	Effectiveness of a comprehensive management program of fragile COPD patients. , 2016, , .		0
119	Transbronchial cryobiopsy in the diagnosis of the idiopathic interstitial pneumonias. , 2016, , .		0
120	<i>Haemophilus influenzae</i> induces steroid-resistant inflammatory responses in COPD. <i>BMC Pulmonary Medicine</i> , 2015, 15, 157.	0.8	17
121	What pulmonologists think about the asthma–COPD overlap syndrome. <i>International Journal of COPD</i> , 2015, 10, 1321.	0.9	35
122	Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations. <i>PLoS ONE</i> , 2015, 10, e0135199.	1.1	62
123	B Cell "Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 695-705.	2.5	89
124	Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD. <i>Chest</i> , 2015, 148, 159-168.	0.4	96
125	Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1261-1270.	2.0	27
126	Determinants of false-negative results in non-small-cell lung cancer staging by endobronchial ultrasound-guided needle aspiration. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 47, 642-647.	0.6	20

#	ARTICLE	IF	CITATIONS
127	Validation of the 'test of the adherence to inhalers' (TAI) for asthma and COPD patients. , 2015, , .		3
128	Difference between asthma and COPD patients in adherence and non-adherence patterns to inhaler devices. , 2015, , .		0
129	LATE-BREAKING ABSTRACT: Prevalence of comorbidities in patients with asthma-COPD overlap syndrome (ACOS) in primary care. , 2015, , .		1
130	Probe-Based Confocal Laser Endomicroscopy Imaging of Endobronchial Hamartomas. <i>Respiration</i> , 2014, 88, 484-486.	1.2	5
131	NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 1497-1506.	2.4	78
132	Network medicine analysis of COPD multimorbidities. <i>Respiratory Research</i> , 2014, 15, 111.	1.4	48
133	Comorbidity in chronic obstructive pulmonary disease. Related to disease severity?. <i>International Journal of COPD</i> , 2014, 9, 1307.	0.9	33
134	Identification of airway bacterial colonization by an electronic nose in Chronic Obstructive Pulmonary Disease. <i>Respiratory Medicine</i> , 2014, 108, 1608-1614.	1.3	55
135	Structure-function relationship in COPD revisited: an in vivo microscopy view. <i>Thorax</i> , 2014, 69, 724-730.	2.7	9
136	Predicción en tiempo real de la malignidad de ganglios linfáticos mediastínicos mediante ecografía endobronquial. <i>Archivos De Bronconeumología</i> , 2014, 50, 228-234.	0.4	15
137	Real-time prediction of mediastinal lymph node malignancy by endobronchial ultrasound. <i>Archivos De Bronconeumología</i> , 2014, 50, 228-234.	0.4	12
138	Clinical Application of the COPD Assessment Test. <i>Chest</i> , 2014, 146, 111-122.	0.4	20
139	Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells. <i>Respiratory Medicine</i> , 2013, 107, 1895-1903.	1.3	22
140	Documento de consenso sobre el fenotipo mixto EPOC-asma en la EPOC. <i>Archivos De Bronconeumología</i> , 2012, 48, 331-337.	0.4	192
141	An investigation of the resolution of inflammation (catabasis) in COPD. <i>Respiratory Research</i> , 2012, 13, 101.	1.4	19
142	Utilidad de la nariz electrónica para el diagnóstico de enfermedades de la vía respiratoria. <i>Archivos De Bronconeumología</i> , 2012, 48, 187-188.	0.4	5
143	Clinical Audit of COPD Patients Requiring Hospital Admissions in Spain: AUDIPOC Study. <i>PLoS ONE</i> , 2012, 7, e42156.	1.1	95
144	Molecular Mechanisms of Inflammation During Exacerbations of Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumología</i> , 2011, 47, 176-183.	0.4	33

#	ARTICLE	IF	CITATIONS
145	The Expression Of Erythropoietin Receptor In Circulating Endothelial Progenitor Cells Is Reduced In Patients With Stable Chronic Obstructive Pulmonary Disease. , 2011, , .		0
146	Mecanismos moleculares de inflamaci3n durante las agudizaciones de la enfermedad pulmonar obstructiva cr3nica. Archivos De Bronconeumologia, 2011, 47, 176-183.	0.4	57
147	Abnormal Levels of Circulating Endothelial Progenitor Cells During Exacerbations of COPD. Lung, 2010, 188, 331-338.	1.4	41
148	Update in Chronic Obstructive Pulmonary Disease 2009. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 655-660.	2.5	23
149	Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax, 2009, 64, 424-429.	2.7	131
150	Theophylline again? Reasons for believing. European Respiratory Journal, 2009, 34, 5-6.	3.1	16
151	Health-Care Quality Standards in Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2009, 45, 196-203.	0.4	10
152	Subphenotypes: the many faces of chronic obstructive pulmonary disease. Therapy: Open Access in Clinical Medicine, 2009, 6, 771-773.	0.2	2
153	Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2006, 117, 1484-1492.	1.5	97
154	Histone deacetylase 2a-mediated deacetylation of the glucocorticoid receptor enables NF-ÎB suppression. Journal of Experimental Medicine, 2006, 203, 7-13.	4.2	581
155	Redox Regulation of Histone Deacetylases and Glucocorticoid-Mediated Inhibition of the Inflammatory Response. Antioxidants and Redox Signaling, 2005, 7, 144-152.	2.5	67
156	Nature of airway inflammation and remodeling in chronic cough. Journal of Allergy and Clinical Immunology, 2005, 116, 565-570.	1.5	137
157	Decreased Histone Deacetylase Activity in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2005, 352, 1967-1976.	13.9	892
158	Increased Expression of Transient Receptor Potential Vanilloid-1 in Airway Nerves of Chronic Cough. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1276-1280.	2.5	365
159	Histone Acetylase and Deacetylase Activity in Alveolar Macrophages and Blood Monocytes in Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 141-147.	2.5	237
160	Theophylline Restores Histone Deacetylase Activity and Steroid Responses in COPD Macrophages. Journal of Experimental Medicine, 2004, 200, 689-695.	4.2	442
161	Glucocorticoid suppression of nuclear factor-ÎB: a role for histone modifications. Biochemical Society Transactions, 2003, 31, 60-65.	1.6	49
162	A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8921-8926.	3.3	461

#	ARTICLE	IF	CITATIONS
163	Endobronchial Hamartoma. Chest, 2002, 122, 202-205.	0.4	133
164	p65-activated Histone Acetyltransferase Activity Is Repressed by Glucocorticoids. Journal of Biological Chemistry, 2001, 276, 30208-30215.	1.6	123